Pure Global
NCT04635306

13C-Spirulina Nitrogen Content GEBT Study

Determination of the Effect of 13C-Spirulina Nitrogen Content on In-vivo 13C-Spirulina Gastric Emptying Breath Test (GEBT) Results
Cairn Diagnostics·ClinicalTrials.gov·diagnostic testTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Gastroparesis
Drug/Device/Intervention
Approved GEBT test meal
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Cairn Diagnostics
Location
Brentwood, United States of America
Timeline & enrollment
Phase
N/A
Start date
Oct 21, 2020
End date
Jun 25, 2021
Enrollment
12 participants
Primary outcome

Difference in vivo 13C-Spirulina GEBT response

Summary

The purpose of this study is to determine whether there is a difference in the human in vivo
 response to 13C-Spirulina meals manufactured using 13C-Spirulina containing different levels
 of protein (as measured by %nitrogen).

ICD-10 classifications
Attention to gastrostomyGastrostomy statusOther gastritisGastritis, unspecifiedGastric diverticulum
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04635306
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04635306 through Pure Global AI's free database. This phase not specified trial is sponsored by Cairn Diagnostics and is currently Terminated. The study focuses on Gastroparesis. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.